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Abstract
Background: Lentiviral vectors are well suited for gene therapy because they can mediate long-
term expression in both dividing and nondividing cells. However, lentiviral vectors seem less
suitable for liver gene therapy because systemically administered lentiviral vectors are preferentially
sequestered by liver macrophages. This results in a reduction of available virus and might also
increase the immune response to the vector and vector products.
Reduction of macrophage sequestration is therefore essential for efficient lentiviral liver gene
therapy.
Results: Fusions were made of Autographa californica GP64 and the hepatocyte specific Sendai
Virus envelope proteins. Lentiviral vectors were produced with either wild type GP64, Sendai-
GP64, or both wild type GP64 and Sendai-GP64 and tested in vitro and in vivo for hepatocyte and
macrophage gene transfer.
Sendai-GP64 pseudotyped vectors showed specific gene transfer to HepG2 hepatoma cells, with
no detectable transduction of HeLa cervical carcinoma cells, and a decreased affinity for RAW
mouse macrophages. Co-expression of wild type GP64 and Sendai-GP64 resulted in improved viral
titers while retaining increased affinity for HepG2 cells.
In vivo, the Sendai-GP64 vectors also showed decreased transduction of murine liver macrophages.
Conclusion: We demonstrate reduced macrophage transduction in vitro and in vivo with GP64/
Sendai chimeric envelope proteins.
Background
HIV-1 derived lentiviral vectors efficiently transfer genes
and mediate long-term gene expression in non-dividing
cells [1-3]. These properties make lentiviral vectors attrac-
tive candidates for the correction of inherited liver disor-
ders. Lentiviral vectors pseudotyped with the envelope
glycoprotein from Vesicular Stomatitis Virus (VSVg) can
efficiently transduce primary hepatocytes in vitro [4,5]. In
contrast, in vivo lentiviral vector delivery in rodents results
in relatively poor gene transfer to hepatocytes because
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[6-8]. We have previously shown that the main target of
VSVg pseudotyped lentiviral vectors are liver macro-
phages, the Kupffer cells [9]. Although depletion of
Kupffer cells leads to a significant increase in the gene
transfer to hepatocytes [9] it would be preferable to
develop lentiviral vectors that are less efficiently seques-
tered by macrophages. This would make more virus avail-
able for hepatocyte transduction and could also reduce
the immune response to the viral vector and vector prod-
ucts.
Lentiviral vectors are commonly pseudotyped with VSVg
which generates stable virions capable of transducing a
broad range of cells both in vitro [10] and in vivo [10,11].
However, because this broad transduction range is not
desireable in many applications, the use of alternative
envelopes is investigated. The envelope protein from the
baculovirus Autographica californica multiple nuclear poly-
hedrosisvirus, GP64, is also able to efficiently pseudotype
lentiviral vectors [12]. GP64 pseudotyped lentiviral vec-
tors exhibit comparable tropism and viral titers as that of
VSVg, but with reduced cellular toxicity [12]. A compari-
son of in vivo gene transfer of lentiviral vectors pseudo-
typed with either VSVg or GP64 showed comparable
transduction profiles in murine livers [13]. Thus,
although earlier reports showed that baculovirus based
vectors displayed a hepatocyte tropism[14,15], pseudo-
typing lentiviral vectors with the baculoviral GP64 protein
does not appear to enhance hepatocyte gene transfer in
vivo.
The engineering of retroviral envelope proteins for retar-
geting represent a challenge as modifications to viral enve-
lope proteins often results in a significant reduction in
viral titers [16-18]. GP64 seems to tolerate peptide inser-
tions better than other viral envelopes and is therefore an
attractive platform for the generation of targeted viruses.
In baculovirus, amino terminal fusions to the GP64 enve-
lope protein have been used for the surface display of;
GFP [19], functional single chain antibody fragments
[20], Plasmodium berghei circumsporozoite protein [21],
avidin [22], and gp120 from HIV [23]. Lentiviral vectors
can also be pseudotyped with engineered GP64 proteins,
decay accelerating factor was fused to the amino terminus
of GP64 and incorporated into lentiviral vector particles
[24]. We have recently shown that GP64 can be used for
the surface display of a peptide from the hepatitis B virus
PreS1 protein resulting in pseudotyped lentiviral vectors
with preferential gene transfer to liver derived cells [25].
The Sendai Virus Fusion (SV-F) protein utilizes a hepato-
cyte specific receptor for viral entry [26]. Both murine ret-
roviral [27] and lentiviral vectors [28] could be
pseudotyped with the SV-F protein, resulting in hepato-
cyte specific gene transfer, but viral particles were unstable
and viral titers were too low to proceed to in vivo studies.
We constructed a Sendai-GP64 fusion protein and investi-
gated the tropism of lentiviral vectors pseudotyped with
this envelope protein for hepatocytes and macrophages in
vitro and in vivo.
Results
Construction of Sendai-GP64 chimeric envelope protein
The Sendai Virus Fusion protein (SV-F) is expressed as an
inactive precursor protein F0, which is cleaved by a cellular
protease to a F1 and F2 chain [29,30] (Figure. 1). A frag-
ment containing the F2 domain and fusion peptide was
fused to the amino terminus of GP64 (Figure 1). The
resulting fusion gene of SV-F and GP64, Sendai-GP64, was
verified by both restriction fragment analysis and
sequencing.
To investigate expression levels and incorporation into
virus particles, Sendai-GP64 pseudotyped lentiviral vector
particles were examined by western blotting. The mono-
clonal antibody (AcV5) directed against GP64 gave the
expected band for the wild type GP64 pseudotyped lenti-
viral vectors (Figure 2 lane 1), but did not react with virus
pseudotyped with Sendai-GP64 recombinant protein
(Figure 2 lane 2). This was unexpected because Sendai-
GP64 pseudotyped lentiviral vectors are capable of trans-
ducing cells and Sendai-GP64 contains the full length
GP64 cDNA. However, the Sendai-GP64 fusion protein
does not contain the native GP64 signal peptide and this
may lead to differential posttranslational modifications
abrogating binding of the AcV5 GP64 antibody. A new
fusion protein was created where the Sendai Fusion F2
domain was inserted after the native signal peptide of
GP64, Sendai-spGP64. Analysis of Sendai-spGP64 pseu-
dotyped lentiviral particles on western blot produced a
band migrating at the predicted size for the fusion protein
(Figure 2 lane 3). However, compared to wtGP64, stain-
ing intensity of the Sendai-spGP64 protein was low. The
Diagram of envelop constructsFigure 1
Diagram of envelop constructs. Linear map of the Sendai 
Virus Fusion (SV-F), wtGP64, Sendai-GP64, and Sendai-
spGP64 glycoproteins with selected domains indicated: SP: 
Signal Peptide, FP: Fusion peptide, TM: Transmembrane.Page 2 of 10
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because it was not consistently present in western blots of
concentrated GP64 virus. This lower band might therefore
represent a degradation product of GP64, but could also
be aspecific staining as more viral particles were loaded in
the lane with Sendai-GP64 and Sendai-spGP64.
Pseudotyping lentiviral vectors with Sendai-GP64 fusion 
proteins
Lentiviral vectors expressing GFP from the PGK promoter
were produced with wtGP64, Sendai-GP64, or Sendai-
spGP64 viral envelope proteins. Viral titers were deter-
mined on both HeLa (a human cervical carcinoma cell
line) and HepG2 (a liver hepatoma cell line) cells. Lenti-
viral vectors pseudotyped with GP64 can efficiently trans-
duce both HeLa and HepG2 cells, while both Sendai-
GP64 and Sendai-spGP64 pseudotyped lentiviral vectors
were only able to transduce HepG2 cells. Thus, both chi-
meric envelope vectors displayed a higher affinity for
HepG2 cells as compared to wtGP64 (Table 1). Viral titers
on HepG2 cells with Sendai-GP64 and Sendai-spGP64
vectors were approximately 2 orders of magnitude lower
than those obtained with wild type GP64 (Table 1).
The titers of lentiviral vectors with either the Sendai-GP64
or Sendai-spGP64 envelope alone were too low for in vivo
use. Therefore, to increase viral titers, lentiviral vectors
were produced with wtGP64 and either Sendai-GP64 or
Sendai-spGP64 envelope proteins. The ratio of wtGP64 to
Sendai-GP64 or Sendai-spGP64 plasmid used during
virus production were optimised to yield lentiviral vectors
that had high titers on HepG2 cells while retaining a
reduced affinity for HeLa cells. The specificities of viruses
produced with different ratio's of wild type GP64 and
Sendai-GP64 are shown in table 2.
We have previously shown that Kupffer cells (liver macro-
phages) are the predominant cell type transduced within
the liver [9]. Therefore, it was important to determine the
relative affinity of Sendai-GP64/wtGP64 and Sendai-
spGP64/wtGP64 lentiviral vectors for macrophages. The
mouse macrophage cell line RAW, was used as model to
assess the relative gene transfer efficiency of our chimeric
lentiviral vectors as compared to wtGP64. Wild type GP64
and Sendai-spGP64/wtGP64 pseudotyped lentiviral vec-
tors were capable of gene transfer to this macrophage cell
line, but titers were lower than those on HepG2 cells.
However, Sendai-GP64/wtGP64 chimeric lentiviral vec-
Detection of GP64 proteins by western blotFigure 2
Detection of GP64 proteins by western blot. Concen-
trated viral vectors pseudotyped with wild type GP64, 
Sendai-GP64, and Sendai-spGP64 were subjected to western 
blotting and GP64 was detected using a monoclonal antibody. 
Lane 1 wtGP64, Lane 2 Sendai-GP64, Lane 3 Sendai-spGP64. 
The lane with wtGP64 pseudotyped virus shows strong reac-
tivity at the expected size, 64 kDa. The higher molecular 
mass band likely represent GP64 trimers. The lane with 
Sendai-spGP64 pseudotyped virus shows reactivity at the 
expected size but at a much lower level. The lower molecu-
lar mass bands in the lanes with Sendai-GP64 and Sendai-
spGP64 likely represent aspecific reactivity.
Table 1: Specificity of GP64 and GP64 variants for hepatoma cells and macrophages.





HepG2 vs RAW 
wtGP64 4.2 × 105 ± 3.1 × 105 2.6 × 106 ± 1.6 × 106 4.0 × 105 ± 3.2 × 105 6.1 0.15 6.5
Sendai-GP64 UDa 2.7 × 104 ± 1.3 × 104 UDa > 27 NDb ND
Sendai-GP64/
wtGP64
1.8 × 104 ± 1.1 × 104 5.1 × 105 ± 2.7 × 105 0.3 × 105 ± 0.2 × 105 28 0.06 17
Sendai-spGP64 UDa 1.2 × 104 ± 0.4 × 104 UDa > 12 NDb ND
Sendai-spGP64/
wtGP64
2.2.104 ± 0.5 × 104 4.1 × 105 ± 1.2 × 105 2.3 × 105 ± 1.3×105 18 0.56 1.8
Lentiviral vectors were pseudotyped with: wild type GP64, Sendai-GP64 fusion protein, or generated with a mix of 29:1 of fusion- to wild type GP64 
expression vector,, were used to transduce HeLa cervical carcinoma cells, HepG2 hepatoma cells and RAW macrophages.
Viral titers were determined using unconcentrated lentiviral vectors from at least two different virus preparations and are expressed as the amount 
of transducing units per ml. Specificity was calculated as the ratio of titers on HepG2 and HeLa cells and as the ratio of titers on RAW macrophages 
and HeLa cells.
a Undetectable with detection limit of viral titers set to 1 × 103 TU/ml with flow cytometry. No GFP expressing cells were observed using a 
fluorescent microscope.
bNot determined.Page 3 of 10
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ing that Sendai-GP64 virus is detargeted from
macrophages. The higher affinity for a hepatoma cell line
(Table 1) and reduced gene transfer to macrophages
(Table 1) suggests that only Sendai-GP64/wtGP64 and
not Sendai-spGP64/wtGP64 lentiviral vectors would
exhibit improved hepatocyte specificity in vivo.
Significant reduction in gene transfer to nonparenchymal 
liver cells in vivo with Sendai-GP64/wtGP64 lentiviral 
vectors
Male FVB mice 6 to 10 weeks old were injected intrapor-
tally with identical amounts of infectious virions, 0.5 ×
108 HepG2 transducing units, of GP64 (6.3 μg HIV p24, n
= 5), Sendai-GP64/wtGP64 (21.3 μg HIV p24, n = 7), or
Sendai-spGP64/wtGP64 (4.6 μg HIV p24, n = 4) pseudo-
typed lentiviral vectors. One week following viral injec-
tions, the mice were sacrificed and tissues were fixed in
vivo. Liver sections were prepared from the left and medial
lobes and GFP expression was directly observed using flu-
orescence microscopy. In liver sections of mice injected
with wtGP64 lentiviral vectors, the majority of transduced
liver cells were nonparenchymal cells (Figure 3B), as pre-
viously described[13]. Staining of these sections with the
F4/80 antibody confirmed that the majority of transduced
non parenchymal cells are liver macrophages, the Kupffer
cells. (Figures 4A-C). Strikingly, in the liver sections from
Sendai-GP64/wtGP64 lentiviral vector injected mice but
not in thet Sendai-spGP64/wtGP64 injected mice, the
ratio of GFP expressing hepatocytes to nonparenchymal
liver cells was much higher (Figures 4C and 4E).
Counting of GFP positive cells in liver sections showed a
significant reduction (p < 0.005) in the amount of trans-
duced nonparenchymal liver cells in mice injected with
Sendai-GP64/wtGP64 lentiviral vectors as compared to
wtGP64 (Table 3). Sendai-spGP64/wtGP64 injected mice
had approximately two fold less gene transfer to hepatoc-
tyes and liver nonparenchymal cells compared to wtGP64
treated mice (p < 0.05). The ratio of GFP positive hepato-
cytes to non-parenchymal liver cells of Sendai-GP64/
wtGP64 pseudotyped lentiviral vectors is three fold
increased as compared to both wtGP64 and Sendai-
spGP64/wtGP64 (Table 3).
Our observation that Sendai-GP64/wtGP64 pseudotyped
lentiviral vectors have a reduced affinity for RAW macro-
phages in vitro is thus confirmed by the lower transduc-
tion of liver macrophages in vivo.
To validate the microscopy data, PCR amplification spe-
cific for integrated lentiviral vectors was performed on
genomic DNA isolated from the liver. In the Sendai-
GP64/wtGP64 and Sendai-spGP64/wtGP64 injected ani-
mals a weaker band is observed in liver genomic DNA,
validating the results from the counting of GFP expressing
cells in liver sections (Figure 5A lanes 3 and 4 versus 5 and
6). Unfortunately, transduction levels were too low for
accurate quantitative PCR.
Discussion
We report the first use of an amino terminal fusion to
GP64 for the targeting of lentiviral vectors in the liver. The
F2 domain of the Sendai virus fusion protein was fused to
the amino terminus of GP64 and used to pseudotype len-
tiviral vectors. Lentiviral vectors pseudotyped with the
Sendai-GP64 and Sendai-spGP64 fusion envelope were
no longer able to transduce HeLa cells, but were still able
to transduce HepG2 cells (Table 1). Viral titers were
increased by co-production of both wild type GP64 and
Sendai-GP64 (Table 2), in agreement with previous
reports of GP64 fusion proteins both in baculoviral [23]
and lentiviral vectors [24]. The presence of wild type GP64
may increase incorporation of Sendai-GP64 proteins into
viral particles through a chaperone function or it may
restore fusion activity that could be lost due to the addi-
tion of the SV-F2 domain [31].
Although Sendai-GP64 pseudotyped lentiviral vectors
were capable of gene transfer, we were unable to detect
expression of this chimeric fusion protein in viral particles
and lysates of transfected cells (not shown) by western
blot. This was surprising because the Sendai-GP64 con-
struct contains the full length GP64 cDNA with exclusion
of the signal peptide.
Lentiviral vectors produced without a viral envelope pro-
tein lack the ability to bind and fuse to target cells and are
not capable of gene transfer in HepG2 cells under our
experimental conditions (Markusic and Seppen, unpub-
lished results). Thus, a functional envelope protein must
be incorporated in the Sendai-GP64 pseudotyped virions.
The most likely explanation for this discrepancy is that
different posttranslational processing of Sendai-GP64
results in disruption of epitopes that are recognised by the
antibody on wild type GP64.
Table 2: Specificity of virus produced with different ratios of 
Sendai-GP64 to wild type GP64.
Ratio HeLa HepG2 Specificity
2:1 2.2 × 105 ± 1.7 × 105 1.6 × 106 ± 1.2 × 106 7.4
9:1 4.5 × 104 ± 2.2 × 104 7.1 × 105 ± 2.1 × 105 15.8
29:1 1.8 × 104 ± 1.1 × 104 5.1 × 105 ± 2.7 × 105 28.9
99:1 2.5.103 ± 1.5 × 103 7.7 × 104 ± 1.6 × 104 30.7
The ratio's 2:1, 9:1, 29:1, 99:1 refer to the relative amount of Sendai-
GP64 to GP64 plasmid used for transfection during virus production. 
Viral titers were determined using unconcentrated lentiviral vectors 
from at least three different virus preparations.Page 4 of 10
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we constructed a Sendai-GP64 fusion protein that uses the
GP64 signal peptide we were able to detect low levels of
Sendai-spGP64 on western blot (Figure 2 lane 3) suggest-
ing that the removal of the native GP64 signal peptide in
Sendai-GP64 may effect protein processing and explain
the loss of reactivity with the GP64 specific antibody
AcV5.
Using the RAW mouse macrophage cell line as model for
Kupffer cells, we showed that while wild type GP64 lenti-
viral vectors can efficiently transduce these cells, Sendai-
GP64/wtGP64 lentiviral vectors transduce these macro-
phages with very low efficiency (Table 2). When adminis-
tered in vivo, Sendai-GP64/wtGP64 lentiviral vectors
exhibited a significant reduction of gene transfer to
Kupffer cells (Table 3). Interestingly, Sendai-spGP64/
wtGP64 pseudotyped lentiviral vectors transduced RAW
mouse macrophages with a similar efficiency as wild type
GP64 alone (Table 2) and this correlated well with
increased gene transfer to Kupffer cells in vivo (Table 3).
These data suggest that RAW mouse macrophages are a
good model for assessing the gene transfer to liver Kupffer
cells in vivo.
We evaluated three different pseudotyped lentiviral vec-
tors (GP64, Sendai-GP64/wtGP64, and Sendai-spGP64/
wtGP64) for in vivo gene transfer to hepatocytes in murine
livers. Using GP64 pseudotyped lentiviral vectors as a ref-
erence, we observed a significant reduction in gene trans-
fer to liver nonparenchymal cells with the Sendai-GP64/
wtGP64 and Sendai-spGP64/wtGP64 lentiviral vectors
(Table 3). Mice receiving Sendai-spGP64/wtGP64 lentivi-
ral vectors had a two fold reduction in both hepatocyte
and liver nonparenchymal cell gene transfer. The Sendai-
spGP64/wtGP64 pseudotyped lentiviral vectors displayed
a lower in vitro specificity for HepG2 cells (Table 1) and
this in part may explain the lower gene transfer efficiency
observed.
Microscopic detection of GFP expression in the liverFigure 3
Microscopic detection of GFP expression in the liver. Expression of GFP in the liver following portal vein injection of 
either wtGP64, Sendai-GP64/wtGP64, or Sendai-spGP64/wtGP64 lentiviral vectors. Sections from the livers of (A) control (B) 
wild type GP64, (C) Sendai-GP64/wtGP64, (D) Sendai-spGP64/wtGP64 transduced mice. Low magnification (10×) fields are 
shown to give a representative view. White arrows indicate hepatocytes and yellow arrows indicate nonparenchymal liver 
cells. In wild type GP64 injected mice most GFP positive cells are nonparenchymal, in Sendai-GP64/wtGP64 injected mice the 
proportion of GFP positive nonparenchymal cells is much lower.Page 5 of 10
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are low and must be improved to be suitable for practical
use. Inserting the Sendai fragment into a different site of
GP64 or using a directed evolution approach might result
in new and improved hybrid viral envelopes.
Hepatocyte specific gene transfer using GP64 pseudo-
typed Feline Immunodeficient Virus (FIV) derived lentivi-
ral vectors has been described [32]. This hepatocyte
specific gene transfer was not observed in our GP64 pseu-
dotyped HIV derived lentiviral vectors (Figures 3B, 4C and
Table 3) and in a previously published comparison of
VSVg and GP64 pseudotyped HIV lentiviral vectors [13].
In both cases there is significant gene transfer to nonpa-
renchymal liver cells. Differences in lentiviral vector sys-
tems and marker gene may explain these differences. In
our hands, decreased nonparenchymal liver cell gene
transfer was only observed with chimeric lentiviral vectors
produced with wtGP64 and either Sendai-GP64 or
Sendai-spGP64 (Figure 2C and Table 3).
Conclusion
In this study we have shown that it is possible to redirect
in vivo gene transfer through manipulations to the GP64
envelope protein. Further improvements in GP64 fusion
proteins allowing for higher levels of expression may
eventually lead to hybrid envelope proteins with com-
plete retargeting without the need to co-express wild type
GP64 envelope protein.
Methods
Construction of hybrid GP64 envelope proteins
The Sendai Virus Fusion cDNA was kindly provided by Dr.
Allen Portner (St. Jude Children's Research Hospital) in a
Immunofluorescent staining of liver macrophagesFigure 4
Immunofluorescent staining of liver macrophages. Liver sections were stained with an antibody against the F4/80 
Kupffer cell marker. Kupffer cells are shown in red, GFP positive cell are shown in green. (A-C) Sections from a wtGP64 trans-
duced mouse (A) GFP (B) Kupffer cells (C) composite. (D-F) Sections from a Sendai-GP64/wtGP64 transduced mouse (D) GFP 
(E) Kupffer cells (F) composite. (G-I) Sections from a Sendai-spGP64/wtGP64 transduced mouse (G) GFP (H) Kupffer cells (I) 
composite. Images are at 400× magnification. Yellow arrows indicate GFP positive Kupffer cells, grey arrows indicate GFP neg-
ative Kuppfer cells, and white stars denote GFP positive hepatocytes. In wild type GP64 and to a lesser extent Sendai-spGP64/
wtGP64 injected mice many GFP positive Kupffer cells are observed. In Sendai-GP64/wtGP64 injected mice the level of Kupffer 
cell tranduction is much lower.Page 6 of 10
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kindly provided by Marcel Westenberg, Wageningen Uni-
versity, and subsequently subcloned into the pCDNA 3.1p
mammalian expression vector. An amino terminal trunca-
tion of GP64 was made by PCR to remove the native sig-
nal peptide (amino acids 1-21) retaining the native GP64
sequence starting at amino acid 25 using the following
primers: ClaI GP64F 5'-GATCATCGATGAACGCGCAAAT-
GAAGACGGGT-3' and GP64R 5'-TGCTGGATATCTGCA-
GAATT-3'. The resulting PCR product was cloned into the
pCR2.1 TOPO TA vector (Invitrogen), pCR2.1 AA25GP64
and verified by sequencing. The Sendai-GP64 fusion con-
struct was created by digestion of pCR2.1 AA25PG64 with
ClaI and EcoRV to release a 1485 fragment containing the
GP64 coding sequence. This fragment was cloned into a
ClaI SmaI digest of the pCAG SV-F vector to create an in-
frame F2-GP64 fusion cDNA. The resulting Sendai-GP64
fusion plasmid was verified by restriction digest and
sequencing. A multiple cloning site containing a ClaI and
AgeI restriction site was introduced immediately after the





The resulting PCR product was ligated into the pCR2.1
TOPO vector and sequenced. The GP64 coding sequence
containing the MCS was released by a KpnI and SacII
digest and subcloned into a KpnI and SacII digest of the
pCDNA 3.1 GP64 to create pCDNA3.1 MCSGP64. The
Sendai Virus F2 coding sequence was amplified with the
following primers ClaISVF2f 5'-ATCGATATGACAGCAT-
ATATCCAGAGATC-3'
ClaISVF2r 5'-ATCGATTCTCGACTGGGGAGCACCGGCAT-3'
The resulting product was verified by sequencing and
cloned into the ClaI site of MCSGP64 to create pCDNA
3.1 Sendai spGP64.
SDS-PAGE and western blotting
Concentrated viral supernatants of GP64, Sendai-GP64/
wtGP64, Sendai spGP64, and Sendai spGP64/wtGP64
pseudotyped lentiviral vectors were run on 10% SDS-
PAGE and blotted onto nitrocellulose using the Bio-Rad
Miniprotean III system. An antibody directed against a C
terminal epitope in the GP64 protein, AcV5 (eBioscience
14-6995), was used at a 1:1000 dilution. A 1:1000 dilu-
tion of Goat anti Mouse HRP (Bio-Rad 170-6516) was
used as a secondary antibody on all blots. Detection of
reactive bands on western blots was performed using the
Lumi-Light western Blot Substrate (Roche 12 015 200
001) and blots were analyzed using a LumiImager F1 and
LumiAnalyst 3.1 software (Roche).
Cell lines and culturing
HEK293T, HeLa, and HepG2 cells were grown in standard
DMEM media supplemented with 10% fetal calf serum
(FCS), 2 mM glutamine, 100 U/ml penicillin, and 100 μg/
ml streptomycin at 37°C in 10% CO2. RAW mouse mac-
rophages were grown in standard RPMI media supple-
Table 3: Transduction efficiency of lentiviral vectors pseudotyped with GP64 variants on hepatocytes and non parenchymal cells of 
murine liver.
Pseudotype Hepatocytes/mm2 NPC/mm2 Specificity
wtGP64 (n = 5) 9.9 ± 2.7 79.3 ± 12.1 0.125
Sendai-GP64/wtGP64 (n = 7) 9.5 ± 4.7 24.6 ± 19.6 a 0.386
Sendai-spGP64/wtGP64 (n = 4) 5.6 ± 1.4b 47.5 ± 19.4b 0.118
Lentiviral vectors pseudotyped with wild type GP64 or mixes of wild type GP64 and Sendai-GP64 fusion proteins were generated and concentrated 
as described.
Mice were injected in the portal vein with 0.5 × 108 HepG2 transducing units of each virus. After one week frozen fixed liver sections were 
prepared from the medial and left lobes and GFP positive cells were counted using a fluorescence microscope.
NPC: nonparenchymal liver cells.
Specificity was calculated as the ratio of GFP positive hepatocytes/mm2 to GFP positive NPC/mm2 and indicates relative affinity for hepatocytes.
a represents a significant difference (p < 0.005) between wtGP64 and Sendai-GP64/wtGP64 transduced animals. b represents a significant difference 
(p < 0.05) between wtGP64 and Sendai-spGP64/wtGP64 transduced animals.
PCR analysis of integrated vector genomesFigure 5
PCR analysis of integrated vector genomes. Genomic 
liver DNA from control mice and mice injected with differ-
ent GP64 pseudotypes was isolated and PCR specific for 
integrated lentiviral vectors was performed. Lanes 1 and 2 
wtGP64, 3 and 4 Sendai-GP64/wtGP64, 5 and 6 Sendai-
spGP64/wtGP64, 7 control liver DNA, 8 water control. The 
strongest signals are seen in wild type GP64 transduced mice, 
confirming that these mice have more total GFP positive cells 
in the liver.Page 7 of 10
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glutamine, 100 U/ml penicillin, and 100 μg/ml strepto-
mycin at 37°C in 10% CO2
Lentiviral vector production
Lentiviral vectors with the phosphoglycerate kinase pro-
moter driving eGFP expression were produced as
described earlier [4]. Briefly, lentiviral vectors were pro-
duced by transient transfection of 293T HEK cells using
calcium phosphate precipitation. Sendai-GP64/wtGP64
pseudotyped lentiviral vectors were produced using 6.8
and 0.2 μg of plasmid per plate respectively. Sendai-
spGP64 pseudotyped lentiviral vectors used 50 μg of enve-
lope plasmid per plate and Sendai-spGP64/wtGP64 used
50 and 0.5 μg of envelope plasmid respectively. Viral
supernatants were concentrated for animal experiments
and western blotting by overnight centrifugation using a
Hettich centrifuge (2230 g). Viral titers were determined
by titration on both HeLa and HepG2 cells. Briefly trans-
ductions were performed for four hours (HeLa and
HepG2) and overnight (RAW) in the presence of DEAE
Dextran (10 μg/ml) and 72 hours later cells were analyzed
by flow cytometry for GFP expression. GFP positive cells
were not observed when viral transductions of HepG2
cells were performed in the presence of the HIV reverse
transcriptase inhibitor AZT (Retrovir) indicating the
absence of pseudotransduction.
Viral particles were measured using a commercial ELISA
kit for the Gag p24 protein (Perkin Elmer NEK050).
HepG2 titers for the concentrated lentiviral vectors ranged
from 1.5 - 3.2 × 108 transducing units/ml and p24 levels
ranged from 4-30 μg/ml.
Animals, viral injections, and tissue processing
Wild-type FVB male mice ages 6-10 weeks were used in all
studies and were fed ad libitum on standard laboratory
chow. All animal experiments were performed in accord-
ance with the Animal Ethical Committee guidelines at the
Academic Medical Center of Amsterdam.
Mice were anesthetized with an intraperitoneal injection
of FFM mix (2.5 mg/ml Fluanisone/0.105 mg Fentanyl cit-
rate/1.25 mg Midozalam HCl/kg in H2O, 7 ml/kg). Under
deep anesthesia, the peritoneal cavity was opened and the
mice were injected intraportally with identical amounts of
infectious virions, the equivalent of 0.5 × 108 HepG2
transducing units, on day 0. The amount of HIV p24
injected was 6.3 μg for GP64, (0.25 ml of 2.0*108 TU/ml
n = 5), 21.3 μg for Sendai-GP64/wtGP64, (0.35 ml of
1.5*108TU/ml) n = 7), and 4.6 μg for Sendai-spGP64/
wtGP64, (0.16 ml, of 3.1*108TU/ml) n = 4. The perito-
neal cavity was sutured and the animals received the anal-
gesic Temgesic (20-30 μl, 0.03 m mg/ml) subcutaneously
following recovering from FFM.
On day 7, the mice were killed by in vivo fixation. Under
deep anaesthesia, the peritoneal cavity was opened and a
ligature was place around the anterior right lobe of the
liver, tightened, and the lobe was excised and snap frozen
in liquid nitrogen for genomic DNA analysis. Subse-
quently, the animals were perfused intracardially with 20
ml of phosphate buffered saline (PBS), followed by 20 ml
of 2% formaldehyde in PBS. Following perfusion, the
liver and spleen were removed and further fixed for 4
hours in 4% formaldehyde in PBS at room temperature.
The fixed tissues were then transferred to 30% sucrose
solution and incubated overnight at 4°C, snap frozen in
liquid nitrogen and stored at -80°C the following day.
Cryosections were made from both the left and medial
lobes. The tissue was embedded in Tissue-Tek OCT
(Bayer) and sections (6 μm) were applied to poly lysine
coated glass slides and enclosed in Vectashield mounting
media (Vector Laboratories).
Immunostaining
Liver sections were prepared as described above and fro-
zen without mounting media. Following thawing at room
temperature sections were washed three times 5 minutes
each in PBS and blocked with 10% Normal Goat Serum in
PBS/0.05% Tween-20 for one hour. Kupffer cells were
stained with a rat anti mouse F4/80 antigen (1:20 Serotec)
for one hour. Slides were washed three times 5 minutes
each in PBS/0.05% Tween-20 and incubated with a goat
anti rat Texas Red conjugated antibody (1:500 Rockland
Immunochemicals) for one hour. Following three wash-
ing steps of 5 minutes each, sections were embedded in
Vectashield mounting media containing DAPI. Images
were captured at (400×) magnification using a fluorescent
microscope (Leica DMRA2).
Cell counting and statistics
GFP positive cells were counted in sections made from the
left and median lobes using a fluorescent microscope
(Leica DMRA2). All sections/slides were prepared and
coded independent of the counter. Identification of
parenchymal and nonparenchymal cells was made based
on morphology as described before [9].
Per animal, one section from the left lobe and median
lobe were counted for GFP positive hepatocytes at (200×).
Three fields (200×) per section were counted for GFP pos-
itive nonparenchymal liver cells. Images of the counted
sections were captured and the surface area of sections was
calculated using Leica FW4000 software. The number of
total hepatocytes per mm2 was estimated by counting
amount of hepatocytes present in one field at (400×).
Data are reported as number of GFP expressing cells per
square millimeter.Page 8 of 10
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ware using the Mann-Whitney U test. Values were deter-
mined to be significantly different with p < 0.05.
Genomic DNA isolation and PCR
Genomic DNA was isolated from snap frozen liver and
spleen tissue using Dneasy tissue kit (Qiagen) according
to manufacturers instructions. The following primer pairs
were used to generate a 274 bp product: HIV-U3 forward
primer 5'-CTGGAAGGGCTAATTCACTC-3' and HIV PSI
reverse primer 5'-GGTTTCCCTTTCGCTTTCAG-3'. This
primer pair is designed to specifically amplify integrated
provirus and thus reduce contamination from amplifica-
tion of the transfer plasmid. Additionally primers directed
against GAPDH were used as a template loading control
GAPDH forward primer 5'-CAATCACCATCTTCCAG-
GAG-3' and GAPDH reverse primer 5'-
TGCCCACAGCCTTGGCAGC-3'. 100 ng of total DNA was
used per PCR reaction using the following conditions:
95°C for 5 minutes, followed by 33 cycles of 95°C for 30
seconds, 55°C for 30 seconds, and 72°C for 30 seconds
with a fill in at 72°C for 10 minutes. Negative control
samples were taken from animals that had not been
injected with virus.
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